What is the recommended nursing assessment frequency for bleeding during the 8 hours following the initial hour of thrombolytic therapy?
Explanation
This question tests knowledge of the specific monitoring schedule for bleeding in a patient receiving thrombolytics, covering the period immediately following the first hour of infusion.
Other questions
What is the primary general use of thrombolytics as described in the pharmacologic profile?
According to the general action and information section, how do thrombolytics such as alteplase, reteplase, and tenecteplase function?
Which of the following is an absolute contraindication for the use of thrombolytics?
Concurrent use of thrombolytics with which of the following drug classes may increase the risk of bleeding?
During the first hour of thrombolytic therapy, how often should the nurse assess the patient carefully for bleeding?
What is a sign of internal bleeding that a nurse should assess for in a patient receiving thrombolytics?
For a patient receiving thrombolytic therapy for coronary thrombosis, what specific monitoring is recommended?
Within what timeframe must Alteplase be administered for a patient with an acute ischemic stroke?
In the event of severe or internal bleeding during thrombolytic therapy, what is the appropriate immediate action regarding blood volume restoration?
What medication may be used as an antidote for thrombolytic toxicity?
What implementation step is recommended prior to initiating thrombolytic therapy to manage potential infusions?
What instruction should be given to a patient receiving thrombolytic therapy regarding personal care to avoid injury?
What is one of the desired outcomes for a patient receiving thrombolytic therapy for an acute ischemic stroke?
When monitoring vital signs for a patient with coronary thrombosis on thrombolytic therapy, which site should be avoided for blood pressure monitoring?
What medication may be ordered to control fever in a patient receiving thrombolytic therapy?
If invasive procedures like arterial punctures must be performed during thrombolytic therapy, how long should pressure be applied to the site?
In patients with acute ischemic stroke who are over 80 years old, what is the recommended administration window for Alteplase?
What is the rationale for assessing a patient on thrombolytics for altered sensorium or neurologic changes?
According to the nursing assessment guidelines, how frequently should vital signs be monitored for a patient receiving thrombolytics for an indication other than coronary thrombosis?
When is systemic anticoagulation with heparin usually started after the completion of thrombolytic therapy?
What is the primary mechanism of action of thrombolytic agents?
Which condition is listed as a precaution, requiring cautious use of thrombolytics, rather than a contraindication?
If a patient receiving thrombolytics for coronary thrombosis develops significant arrhythmias, what prophylactic medications may be ordered?
What is a key patient teaching point regarding hypersensitivity reactions to thrombolytics?
Which type of invasive procedure should be specifically avoided at noncompressible sites like the jugular or subclavian vein during thrombolytic therapy?
For a patient with acute ischemic stroke and a baseline National Institutes of Health Stroke Scale score of 25 or more, what is the administration window for Alteplase?
Why should laboratory tests such as hematocrit, hemoglobin, and platelet count be evaluated prior to and frequently throughout thrombolytic therapy?
What is a primary desired outcome of thrombolytic therapy in a patient with a thrombosed cannula or catheter?
Concurrent use of thrombolytics with cefotetan, cefoperazone, or valproic acid may have what effect?
What is the rationale for beginning thrombolytic therapy as soon as possible after the onset of symptoms for an acute MI or stroke?
A patient receiving a thrombolytic develops rales, crackles, dyspnea, and an S3 heart sound. What potential complication do these signs indicate?
What is the primary action of alteplase when used for acute pulmonary embolism?
What is a critical lab test consideration that should be arranged before initiating thrombolytic therapy in case of hemorrhage?
A patient receiving thrombolytic therapy has a hematocrit that drops significantly. This is most likely indicative of what?
What instruction is given regarding the handling of a patient during thrombolytic therapy?
Which of the following is NOT listed as a contraindication for thrombolytic therapy?
What is the consequence of the interaction between thrombolytics and NSAIDs?
When assessing a patient for cannula or catheter occlusion, what is the recommended indicator of patency?
In case of a local bleed at an IV site during thrombolytic therapy, what is the initial nursing action?
Why is it important to test stools for occult blood and urine for hematuria periodically during thrombolytic therapy?
For which potential nursing diagnosis is 'avoiding invasive procedures' a key implementation?
What is the primary therapeutic effect of a thrombolytic agent?
A patient with a history of both stroke and diabetes presents with an acute ischemic stroke. What is the administration window for Alteplase in this patient?
When is it appropriate to monitor a patient's breath sounds and heart sounds frequently during thrombolytic therapy?
In addition to alteplase, which two other drugs are mentioned as directly activating plasminogen?
A patient is receiving thrombolytic therapy for a pulmonary embolism. Which set of parameters should the nurse monitor specifically for this indication?
If uncontrolled bleeding occurs during thrombolytic therapy, what is the immediate action regarding the medication?
Which of these is NOT a desired outcome of thrombolytic therapy?
What is the primary reason to avoid using dextran in a patient experiencing severe bleeding from thrombolytic therapy?